ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 1.61 USD -1.23%
Market Cap: 71.5m USD
Have any thoughts about
ESSA Pharma Inc?
Write Note

ESSA Pharma Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ESSA Pharma Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
ESSA Pharma Inc
NASDAQ:EPIX
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bright Minds Biosciences Inc
CNSX:DRUG
Depreciation & Amortization
CA$72.5k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Depreciation & Amortization
$2.8m
CAGR 3-Years
-31%
CAGR 5-Years
-17%
CAGR 10-Years
17%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Depreciation & Amortization
$19.5m
CAGR 3-Years
99%
CAGR 5-Years
67%
CAGR 10-Years
28%
Covalon Technologies Ltd
XTSX:COV
Depreciation & Amortization
CA$949.1k
CAGR 3-Years
12%
CAGR 5-Years
13%
CAGR 10-Years
12%
Spectral Medical Inc
TSX:EDT
Depreciation & Amortization
CA$238k
CAGR 3-Years
-8%
CAGR 5-Years
-2%
CAGR 10-Years
0%
No Stocks Found

ESSA Pharma Inc
Glance View

Market Cap
71.5m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
8.8 USD
Undervaluation 82%
Intrinsic Value
Price

See Also

Back to Top